Four questions, with their evidence
Bring the evidence into the conversation.
Read a consultation question beside the evidence it draws on and the part a public document cannot answer. These four fixed records help organize a discussion; they do not evaluate your health.
This reader provides no personal eligibility decision, medicine regimen, procedure clearance or withholding and restart instructions. Questions about an actual prescription or procedure belong with the responsible clinical teams. Routine website reading or messaging must not delay urgent care.
What health problem is the proposed treatment meant to address?
Current evidence
Wegovy labeling specifies uses and populations for that approved product. NIDDK describes considering medical circumstances, expected benefit, adverse effects and other medicines. CoreAge advertises a compounded, longevity-oriented microdosing program; that description is not evidence of longer life from its exact preparation.
What remains unknown
A public offer does not identify a reader's diagnosis, establish personal eligibility or show that a broad wellness aspiration will be achieved.
Read the source records
Wegovy prescribing information, revised June 2026 →NIDDK: Prescription Medications to Treat Overweight and Obesity →CoreAge Rx: Semaglutide Microdosing Therapy →A question to take to the visit
What are you assessing in this consultation, which evidence supports the proposed goal, and what information would you use to review it later?
Which finished medicine, form and route are being discussed?
Current evidence
The June 2026 Wegovy record includes oral tablets and injection, with indication differences between them. FDA distinguishes an active ingredient from a finished drug product and states that compounded drugs do not receive premarket approval. Sharing an ingredient name does not establish identical product evidence.
What remains unknown
A program title does not provide the complete supplied formula, pharmacy identity or instructions for an individual prescription. An approved tablet does not validate an unspecified alternative preparation.
Read the source records
Wegovy prescribing information, revised June 2026 →FDA: Drugs@FDA Glossary of Terms →FDA: Understanding the Risks of Compounded Drugs →A question to take to the visit
Can you name the proposed preparation and explain which product information supports its intended use, including who will confirm the pharmacy record?
Who will coordinate this medicine with a planned procedure?
Current evidence
Wegovy labeling describes delayed stomach emptying and aspiration reports during general anesthesia or deep sedation. The label cannot establish whether changed fasting advice or temporarily withholding the medicine reduces retained stomach contents. ASA guidance calls for coordination among the prescribing, surgical and anesthesia teams.
What remains unknown
This publication cannot clear a procedure or decide whether a medicine should be continued, withheld or restarted. A microdosing description does not settle those questions.
Read the source records
Wegovy prescribing information, revised June 2026 →American Society of Anesthesiologists: Multi-society GLP-1 guidance, October 2024; updated February 2025 →American Society of Anesthesiologists: GLP-1 medicines and surgery, reviewed October 2025 →A question to take to the visit
Which clinicians will reconcile the actual medicine and procedure information, provide the individual plan and handle changes or conflicting instructions?
Who will review benefit, new concerns and changes in care?
Current evidence
NIDDK describes weighing medicine benefits and adverse effects in the context of individual health. The Wegovy Medication Guide asks patients to share relevant conditions, medicines and procedure plans. Those records support an ongoing clinical conversation rather than judging treatment from a refill or marketing testimonial.
What remains unknown
Public messaging and check-in claims do not verify an individual clinical assessment, response time or emergency-care arrangement. A favorable observation alone cannot establish an unmeasured long-term outcome.
Read the source records
NIDDK: Prescription Medications to Treat Overweight and Obesity →Wegovy prescribing information, revised June 2026 →A question to take to the visit
Who is responsible for reviewing the intended goal and safety concerns, and how will questions that need prompt attention reach the appropriate care team?
These prompts organize a conversation. They are not a checklist for approving treatment. Open whichever discussion prompt is useful to your reading; the evidence and unanswered questions remain above it.